Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cryopreservation of White Blood Cells Before Their UVA Irradiation for Graft Versus Host Disease Treatment (cryo-ECP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03361254
Recruitment Status : Unknown
Verified November 2017 by Central Hospital, Nancy, France.
Recruitment status was:  Not yet recruiting
First Posted : December 4, 2017
Last Update Posted : December 4, 2017
Sponsor:
Information provided by (Responsible Party):
Central Hospital, Nancy, France

Brief Summary:

Extracorporeal photopheresis (ECP) is a worldwide recognized treatment of acute and chronic mild to moderate graft versus host disease (GVHD), in second or further line of treatment. Contrary to immunosuppressive drugs, ECP is not associated with side effects such as opportunistic infections, and is not associated with a higher frequency of relapse of the initial hematological disease. High intensity of ECP regimen (1 to 3 sessions per week, in case of chronic or acute GVHD) seems to be correlated to a higher efficacy. However, high intensity of ECP treatment is often difficult to sustain, because of frequent logistical problems to perform aphereses, such as venous access failure, infections of central line, deep blood cytopenias that require many transfusions before performing aphereses. Merlin et al. first described the feasibility of white blood cells cryopreservation before UVA irradiation, in vitro, then in vivo. We also recently reported the feasibility and efficacy of cryopreserved ECP in a series of 20 patients (adults and children), with acute and chronic GVHD, who had recurrent contraindications to aphereses, that prevented the realization of an intensive program of ECP. No adverse events occurred, and efficacy seemed to be similar to "classical" ECP (35% of complete overall response, and 40% of partial response). White blood cells (WBC) were divided after collection on Optia or Cellex apheresis machines: one was immediately treated with 8-MOP (methoxsalen) and ultraviolet A (UVA) irradiation, while the other was cryopreserved, and further (a few days later) thawed, sensitized with 8-MOP and irradiated before injection to the patient.

The aim of this study is to analyze this method in a prospective way, with complete biological data collection, of apoptosis, cytokines release etc…, necessary to the full description of cryopreservation of white blood cells before their irradiation and reinjection to the patient.

We will propose this technique of cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months.


Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Biological: cryopreservation Not Applicable

Detailed Description:

The main objective of this prospective interventional pilot study is to demonstrate the ability of this technique to follow high intensity regimen recommendations, as mentioned above:

  • 3 ECP sessions (thawed or fresh) per week during 3 months for grade III to IV acute GVHD, then
  • 2 ECP sessions (thawed or fresh) per week during 3 months for grade II acute GVHD
  • 1 ECP session per week for chronic GVHD during 3 months

The other objectives are:

  • To describe the safety and efficacy of cryo ECP. Efficacy will be assessed with a composite criteria test, comporting 5 items, which will be compared for each patient with a paired cohort of historical patients treated in Nancy University Hospital since 2010 (match will be made on type and grade of GVHD, and age under and over 18 year-old)
  • To fully describe the biological consequences of cryopreservation of WBC before UVA irradiation: apoptosis rate and time, lymphocyte functional tests (lymphoblastic transformation test), cytokines release, number of lymphocytes, and monocytes at the time of reinjection, bacteriological tests, residual diméthylsulfoxyde (DMSO) quantification
  • To demonstrate the decrease in red blood cells and platelets transfusion number, due to the sparing effect of cryo ECP on aphereses number.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5 participants
Intervention Model: Single Group Assignment
Intervention Model Description: demonstrate the ability of this technique to follow high intensity regimen recommendations
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Division and Cryopreservation of Autologous Blood Nuclear Cells for Intensive Regimen of Extracorporeal Photopheresis : Interest for the Treatment of Patients With Steroid Resistant Graft Versus Host Disease
Estimated Study Start Date : March 31, 2018
Estimated Primary Completion Date : June 30, 2018
Estimated Study Completion Date : September 30, 2018

Resource links provided by the National Library of Medicine



Intervention Details:
  • Biological: cryopreservation
    cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months


Primary Outcome Measures :
  1. intensity of ECP regimen [ Time Frame: 3 months after the first ECP session ]
    Number of ECP (fresh and thawed) sessions during 3 months


Secondary Outcome Measures :
  1. systemic infections during 3 months after cryo-ECP (safety) [ Time Frame: at 6 weeks and 3 months after the first ECP session ]
  2. occurrence of death after cryo-ECP (safety) [ Time Frame: at 6 weeks and 3 months after the first ECP session ]
  3. occurrence of relapse of the initial hematological disease after cryo-ECP (safety) [ Time Frame: at 6 weeks and 3 months after the first ECP session ]
  4. Steroid sparing effect (efficacy) [ Time Frame: at 6 weeks and 3 months after the first ECP session ]
  5. GVHD grade (severity) (efficacy) [ Time Frame: at 6 weeks and 3 months after the first ECP session ]
  6. immunosuppressive drugs used (efficacy) [ Time Frame: at 6 weeks and 3 months after the first ECP session ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult or child who received an allogeneic hematopoietic stem cell transplantation, with a medical follow-up at the University Hospital of Nancy, or at the other University Hospitals in the great East region (Dijon, Reims, Besançon) in which ECP is not accessible.
  • Eligible for ECP for the treatment of acute or chronic steroid refractory GVHD, after pluridisciplinary concertations
  • Patients (or parents) who received full information on the research and who signed a consent for this research

Non inclusion Criteria:

  • Children under 10 kg of weight
  • Patients or parents who did not sign a consent
  • Patients who present an absolute contra-indication for apheresis: recent pulmonary embolism, deep vein thrombosis, myocardial infarction, active and evolutive bacterial or fungal infection, hemodynamics instability, deep anemia (Hb < 8g/dl) or deep thrombocytopenia (< 20 g/L) despite transfusions, severe hypocalcemia.
  • Women in age to procreate without contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03361254


Contacts
Layout table for location contacts
Contact: Cécile POCHON, Dr. 00 33 3 83 15 46 28 c.pochon@chru-nancy.fr

Sponsors and Collaborators
Central Hospital, Nancy, France

Layout table for additonal information
Responsible Party: Central Hospital, Nancy, France
ClinicalTrials.gov Identifier: NCT03361254     History of Changes
Other Study ID Numbers: APJC2015/CRYOPCE-POCHON/NK
First Posted: December 4, 2017    Key Record Dates
Last Update Posted: December 4, 2017
Last Verified: November 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases